Genmab Announces Patent Settlement Agreement for Ofatumumab


- GSK enters patent settlement with Genentech regarding ofatumumab
- Patents relate to recombinant antibody production
- Financial details of settlement not disclosed

Copenhagen, Denmark; March 26, 2012 — Genmab A/S (OMX: GEN) announced today that GlaxoSmithKline (GSK) has agreed a settlement with Genentech Inc. and City of Hope (a California not-for-profit organization) concerning two U.S. patents that relate to recombinant antibody production for ofatumumab. GSK is Genmab's development and commercial collaborator for the CD20 antibody ofatumumab. The dispute concerned U.S. Patents No 6,331,415 and U.S. No 7,923,221 (the Cabilly II and Cabilly III patents) issued to Genentech, Inc. and City of Hope. No further terms of the settlement are disclosed.

The case was initiated by GSK in October 2009 and has been pending before the United States District Court for the Central District of California. The settlement means that the pending court case will now be concluded. The two patents are due to expire in December 2018.

The settlement is not expected to affect Genmab's financial guidance for 2012.

About Genmab A/S

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.  Founded in 1999, the company's first marketed antibody, ofatumumab (Arzerra®), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab after less than eight years in development.  Genmab's validated and next generation antibody technologies are expected to provide a steady stream of future product candidates.  Partnering of innovative product candidates and technologies is a key focus of Genmab's strategy and the company has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit

Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communication
T: +45 33 44 77 20; M: +45 25 12 62 60; E:

This Company Announcement contains forward looking statements. The words "believe", "expect", "anticipate", "intend" and "plan" and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab's most recent financial reports, which are available on Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab®; the Y-shaped Genmab logo®; HuMax®; HuMax-CD20®; HuMax®-EGFr; HuMax®-IL8; HuMax®-TAC; HuMax®-CD38; HuMax®-TF; HuMax®-Her2; HuMax®-cMet, HuMax®-CD74, DuoBody™ and UniBody® are all trademarks of Genmab A/S. Arzerra® is a trademark of GlaxoSmithKline.

Company Announcement no. 06
CVR no. 2102 3884

Genmab A/S
Bredgade 34
1260 Copenhagen K